H.R. 9090: Advancing Menopause Care and Mid-Life Women’s Health Act

The Advancing Menopause Care and Mid-Life Women's Health Act aims to improve healthcare for women experiencing menopause by increasing research, enhancing public health initiatives, and providing better training for healthcare providers. Key provisions include: 1) Authorizing the National Institutes of Health (NIH) to expand research on menopause and related health impacts, including grants for developing new treatments and diagnostic tools. 2) Directing the Department of Health and Human Services (HHS) to promote public health efforts focused on early detection and treatment of menopausal symptoms, and to improve access to mental health services for affected women. 3) Establishing a national awareness campaign to educate the public and healthcare providers about menopause and mid-life women's health. 4) Creating training programs for healthcare professionals to better manage menopausal symptoms. 5) Designating Centers of Excellence to advance research and training in menopause care. 6) Requiring HHS to report on federal research activities and barriers to care, and to coordinate with other federal agencies on related health initiatives. The bill proposes funding of $25 million annually from 2027 through 2031 for NIH research, and $10 million annually for public health awareness and training programs.

Supporters of the Advancing Menopause Care and Mid-Life Women's Health Act commend its comprehensive approach to addressing a long-neglected area of women's health. They highlight the bill's potential to fill critical gaps in research, improve healthcare provider education, and raise public awareness about menopause. Advocates emphasize that the proposed funding and establishment of Centers of Excellence could lead to significant advancements in treatment options and overall care for mid-life women. The bipartisan nature of the bill is also praised, reflecting a shared commitment to enhancing women's health across political lines.

Critics of the Advancing Menopause Care and Mid-Life Women's Health Act express concerns about the allocation of federal funds, questioning whether the proposed $25 million annually for research and $10 million for public health initiatives are the most effective use of resources. Some argue that the bill may duplicate existing programs or that the focus on menopause could divert attention from other pressing health issues. Additionally, there are apprehensions about the implementation of the Centers of Excellence, with skeptics questioning their potential impact and sustainability.

While there are no direct industry overlaps detected between the sponsor's top donor industries and the subject matter of H.R. 9090, there are notable lobbying activities that could raise concerns. Paratek Pharmaceuticals, which has contributed $20,000, operates in the pharmaceutical sector, and their interests could align with aspects of women's health care, particularly in menopause treatments. Additionally, Steelships, LLC has contributed $45,000, although the specific nature of their business is not disclosed, which adds a layer of uncertainty regarding potential conflicts. Given the lack of direct donor industry overlap, the risk remains moderate but should be monitored closely by voters.

Organizations that lobbied on issues related to this bill's policy area.

Source: Senate Lobbying Disclosure Act (LDA) filings, 2026

Top industries funding Yvette Clarke, ranked by total contributions.

Source: OpenSecrets.org (Center for Responsive Politics)